Bone Up on Hormone Replacement Therapy
WebMD News Archive
April 13, 2001 -- After menopause, women start to lose bone in critical areas of the skeleton, placing them at risk for bone fractures. For years now, experts have said that taking hormone replacement therapy after menopause is one of the best ways to slow bone loss and prevent these fractures and the loss of height that occurs as women age. Now a new study says that in women who don't actually have osteoporosis, hormone replacement may not be doing the trick.
Bone loss is linked to the sharp decline in a woman's natural levels of the hormone estrogen that occurs around menopause. Significant bone loss leads to the brittle-bone disease osteoporosis.
Although studies in women with osteoporosis have indicated that hormone replacement therapy may substantially reduce fracture risk, results of studies conducted in women without osteoporosis have been mixed.
And these new findings, published in the April 15 issue of the American Journal of Medicine, don't help to clarify the situation much.
The study raises suggests that hormone replacement therapy, or HRT, may not be effective at preventing fractures among women who don't have established osteoporosis, says study author Jane Cauley, DrPh, of the University of Pittsburgh. She says any usefulness of the therapy in preventing fractures may be restricted to those women who already have the brittle-bone disease.
The four-year study of more than 2,700 women aged 44-79 found no difference in the incidence of fractures and no difference in height loss between women taking hormone replacement -- either estrogen alone or estrogen plus progestin -- and women taking no hormones.
But Robert Recker, MD, disagrees that this new study rules out HRT or estrogen as an effective way to reduce fractures. He argues this because of the way the study was conducted. Although the authors collected data on fractures, the main goal of the study was to study the effect of the hormones on heart disease -- not the effect on fractures.
And because the women in the study did not have osteoporosis, he says, there is no way to know that they would be the best candidates for the therapy.